VerImmune, Inc. Announces Issuance of Second U.S Patent Protecting Proprietary Technology Platform

Share Article

Newly issued United States patent will provide further protection and support for the Company’s proprietary position in the USA.

VerImmune, Inc. (“VerImmune”), a biotechnology company leading the way in developing virus-inspired particle modalities for cancer treatment, is proud to announce the issuance of its second U.S. Patent from the U.S. Patent and Trademark Office (USPTO). The newly issued patent, U.S. Patent No. 11,560,408 entitled "Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors," provides further protection and support for VerImmune's proprietary technology platform, including the composition of matter and methods of use in treating cancer. The patent is expected to offer protection until at least 2038.

VerImmune's platform redirects the body's pre-existing T-cell memory against pathogens to attack cancer and could potentially act against multiple types of cancer due to the near-universal nature of pre-existing responses to childhood vaccines and past infections. As such, this technology has potentially broad treatment applications.

"The issuance of this second patent is a testament to VerImmune's growing global intellectual property estate, now boasting over 30 patent applications worldwide. This is a key factor in VerImmune's mission to innovate and optimize the clinical and commercial potential of its assets.” said Joshua Wang, Founder and CEO of VerImmune.

About VerImmune
VerImmune is a biotechnology company developing a novel first-in-class cancer therapy known as Anti-tumor Immune Redirection (AIR). This strategy utilizes a proprietary virus-inspired particle (ViP) technology platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have un-treatable cancers due to limited options or experience cancer treatment resistance. For more information, visit

Forward-Looking Statements
Any statements in this release that are not historical facts may be considered to be “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding the market opportunity for VerImmune’s product candidates; and the business strategies and development plans of VerImmune. Some of the potential risks and uncertainties that could cause actual results to differ from those expected include VerImmune’s ability to: make commercially available its products and technologies in a timely manner or at all; enter into other strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, VerImmune does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Follow >